Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript

Integrity: Revenue more than doubled to approximately $6 million in 2025, marking its seventh consecutive quarter of sequential growth. Over 2,500 surgeries have been performed with more than 300 surgeons using the product. New size introductions and expanding tendon applications supported growth.

Hyalofast: Submitted the third and final module of the PMA to the FDA in Q4 2025. While the study did not achieve its prespecified co-primary endpoints, it demonstrated statistically significant improvements across key measures of pain and function. Actively engaging with the FDA to address deficiencies.

Cingal: Surpassed 1 million injections across more than 40 international markets. Initiated and completed required toxicity studies in 2025. Bioequivalence study initiated in December 2025, keeping the product on track for NDA submission.

International OA Pain Management Portfolio: Delivered 28% revenue growth in Q4 and 12% for the full year 2025. Products like Monovisc, Orthovisc, and Cingal gained market share internationally.

Manufacturing Productivity: Improved manufacturing productivity, higher yields, and increased throughput contributed to expanded gross margins and positive operating income in Q4 2025.

Organizational Restructuring: Streamlined leadership layers and reduced expenses, resulting in $2.5 million in annualized headcount savings and over $3 million in stock-based compensation savings.

Revenue Growth Focus: Prioritized sustainable revenue growth through the commercial channel, reducing reliance on OEM partners and diversifying revenue sources.

Innovation Pipeline: Focused on advancing HA-based products like Integrity, Hyalofast, and Cingal to address large underserved markets.

Operational Execution: Strengthened operational execution to improve manufacturing productivity and streamline organizational design for better profitability and cash generation.

Regulatory hurdles: The FDA issued a deficiency letter related to CMC and clinical data for Hyalofast, and there is no assurance of FDA approval. This could delay or prevent market entry for the product in the U.S.

Pricing pressures in OEM channel: The U.S. OA pain management pricing environment remains challenging, leading to a 12% decline in OEM revenue in Q4 and a 17% decline for the full year 2025. This impacts overall profitability and revenue stability.

Operational execution risks: While operational improvements have been made, there is a risk that manufacturing productivity, yield, and capacity improvements may not be sustained, potentially impacting gross margins and profitability.

Dependence on key partnerships: The company relies on its OEM partner, J&J MedTech, for a significant portion of its revenue. Any instability or changes in this partnership could adversely affect financial performance.

Product pipeline risks: The bioequivalence study for Cingal is still underway, and any delays or failures in this study could impact the timeline for NDA submission and market entry in the U.S.

Cost management challenges: While cost reduction measures have been implemented, including leadership changes, there is a risk that these may not yield the expected $2.5 million in annualized savings, impacting profitability.

Market dynamics: The company faces competitive pressures and market dynamics that could affect the adoption of its products, particularly in the U.S. OA pain management market.

Revenue Growth: Anika expects total company revenue for 2026 to be between $114 million and $122.5 million, representing a 1% to 9% year-over-year growth. The commercial channel is projected to grow by 10% to 20% year-over-year, reaching $53 million to $58 million, driven by the expansion of Integrity in the U.S., sustained Hyalofast performance outside the U.S., and increasing adoption of the international OA pain management portfolio. The OEM channel is expected to remain flat or decline by up to 5%, with revenue between $61 million and $64.5 million.

Profitability: Adjusted EBITDA for 2026 is expected to be between 5% and 10% of revenue. This improvement is attributed to higher expected revenue, G&A cost reduction actions, leadership changes, and productivity and manufacturing gains, partially offset by lower U.S. OEM pricing dynamics.

Pipeline Advancements: Hyalofast's PMA submission to the FDA is under review, with active engagement to address deficiency letters. Cingal's bioequivalence study, initiated in December 2025, is underway, keeping the company on track for NDA submission. Integrity's post-market clinical study is past the halfway point, with enrollment expected to complete in 2026, supporting future growth in the U.S. and international markets.

Operational Execution: The company plans to continue improving manufacturing productivity, yield, and capacity to support growth in both commercial and OEM channels. Recent organizational changes, including leadership role eliminations and releveling, are expected to drive $2.5 million in annualized headcount savings and $3 million in stock-based compensation savings, enhancing profitability and cash generation.

Share Repurchase Program: Anika initiated a $15 million 10b5-1 stock repurchase plan in November 2025. In the fourth quarter, the company purchased $5.5 million worth of common stock. To date, the company has purchased $10.7 million in stock, and the program is expected to be complete in the second quarter of 2026.